Quantities of cells infused into patients, according to mononuclear cell subset and source of hematopoietic cells (marrow or blood)
| MNC subset . | Marrow . | Blood3-150 . | Fold increase3-151 . |
|---|---|---|---|
| B cells (total) | 4 (1-25) | 71 (6-141) | 18 |
| Naive (IgD+) | 3 (1-22) | 62 (22-129) | 20 |
| Memory (IgD−) | 0.8 (0.1-3.1) | 9.6 (0.9-33.8) | 12 |
| CD4 T cells (total) | 14 (2-29) | 174 (64-414) | 12 |
| Naive (CD45RAhigh) | 6 (0-16) | 60 (19-233) | 10 |
| Memory or effector (CD45RAlow/−) | 8 (1-25) | 115 (1-204) | 14 |
| Costimulation competent (CD28+) | 14 (1-30) | 156 (57-348) | 11 |
| Costimulation incompetent (CD28−) | 0.4 (0.0-12.8) | 4.0 (0.8-50.7) | 10 |
| CD8 T cells (total) | 10 (1-31) | 82 (22-254) | 8 |
| Naive (CD11alow) | 4 (0-13) | 34 (15-114) | 9 |
| Memory or effector (CD11ahigh) | 7 (1-17) | 34 (7-106) | 5 |
| Costimulation competent (CD28+) | 7 (1-20) | 55 (16-142) | 8 |
| Costimulation incompetent (CD28−) | 3 (0-8) | 11 (2-49) | 4 |
| CD4−CD8− T cells | 0.6 (0.1-2.9) | 4.8 (0.9-19.5) | 8 |
| CD8+CD8+ T cells | 1.0 (0.1-7.9) | 6.5 (0.8-101.6) | 7 |
| Natural killer cells | 3 (0-13) | 30 (13-71) | 10 |
| Monocytes3-152 | 26 (0-111) | 547 (150-2142) | 21 |
| “Stem cells” | 2.5 (1.0-8.0) | 7.4 (1.0-17.5) | 3 |
| B-cell progenitors | 4 (0-22) | 0 (0-2) | 0 |
| Plasma cells | 0.5 (0.0-4.7) | 0.0 (0.0-0.7) | 0 |
| MNC subset . | Marrow . | Blood3-150 . | Fold increase3-151 . |
|---|---|---|---|
| B cells (total) | 4 (1-25) | 71 (6-141) | 18 |
| Naive (IgD+) | 3 (1-22) | 62 (22-129) | 20 |
| Memory (IgD−) | 0.8 (0.1-3.1) | 9.6 (0.9-33.8) | 12 |
| CD4 T cells (total) | 14 (2-29) | 174 (64-414) | 12 |
| Naive (CD45RAhigh) | 6 (0-16) | 60 (19-233) | 10 |
| Memory or effector (CD45RAlow/−) | 8 (1-25) | 115 (1-204) | 14 |
| Costimulation competent (CD28+) | 14 (1-30) | 156 (57-348) | 11 |
| Costimulation incompetent (CD28−) | 0.4 (0.0-12.8) | 4.0 (0.8-50.7) | 10 |
| CD8 T cells (total) | 10 (1-31) | 82 (22-254) | 8 |
| Naive (CD11alow) | 4 (0-13) | 34 (15-114) | 9 |
| Memory or effector (CD11ahigh) | 7 (1-17) | 34 (7-106) | 5 |
| Costimulation competent (CD28+) | 7 (1-20) | 55 (16-142) | 8 |
| Costimulation incompetent (CD28−) | 3 (0-8) | 11 (2-49) | 4 |
| CD4−CD8− T cells | 0.6 (0.1-2.9) | 4.8 (0.9-19.5) | 8 |
| CD8+CD8+ T cells | 1.0 (0.1-7.9) | 6.5 (0.8-101.6) | 7 |
| Natural killer cells | 3 (0-13) | 30 (13-71) | 10 |
| Monocytes3-152 | 26 (0-111) | 547 (150-2142) | 21 |
| “Stem cells” | 2.5 (1.0-8.0) | 7.4 (1.0-17.5) | 3 |
| B-cell progenitors | 4 (0-22) | 0 (0-2) | 0 |
| Plasma cells | 0.5 (0.0-4.7) | 0.0 (0.0-0.7) | 0 |
Values are median (range) number of cells × 106/kg of body weight of recipient. The difference between the marrow and the blood stem cell graft was significant for all the cell subsets (P < .001).
For abbreviations, see Table 2.
Eighteen recipients of blood stem cells received 2 MNC apheresis products. The values given represent the sum of the 2 products.
Median for blood stem cell grafts compared with median for marrow grafts.
When monocytes were defined as CD14highinstead of CD14+ MNCs, median values were 2 × 106/kg for marrow cells and 221 × 106/kg for blood stem cells (a 111-fold increase).